Определение резистентности Candida spp. к антифунгальным препаратам системного действия эпсилометрическим методом (Е-тест) с учетом видо-специфических особенностей кандид


https://doi.org/10.22625/2072-6732-2015-7-3-91-102

Полный текст:


Аннотация

Оценка чувствительности антифунгальных препаратов системного действия к Candida spp. в последние годы была стандартизирована и уточнена с учетом видо-специфических особенностей кандид. В дополнение к новым значениям клинических ключевых точек было введено новое понятие – эпидемиологическое пороговое значение. Его величина может служить надежным  аркером потенциальной резистентности кандид к антимикотикам. В нашем исследовании была протестирована резистентность эпсилометрическим методом (Е-тест) к флуконазолу, вориконазолу, позаконазолу анидулафунгину, каспофунгину, микафунгину для 294 клинических штаммов Candida spp. (2012–2014 гг.), полученных от онкологических больных. Резистентность к азолам в среднем наблюдалась в 47,4% случаях, к эхинокандинам – в 4,2% случаях.


Об авторах

Н. С. Багирова
Российский онкологический научный центр им. Н.Н. Блохина, Москва, Россия
Россия

ведущий научный сотрудник лаборатории микробиологической диагностики и лечения инфекций в онкологии Российского онкологического научного центра им. Н.Н. Блохина, д.м.н.; тел.: +7-916-247-17-69



Н. В. Дмитриева
Российский онкологический научный центр им. Н.Н. Блохина, Москва, Россия
Россия

заведующая лабораторией микробиологической диагностики и лечения инфекций в онкологии Российского онкологического научного центра им. Н.Н. Блохина, д.м.н., профессор; тел. +7-985-070-75-44



Список литературы

1. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts—third edition. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA

2. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; 3rd informational supplement. CLSI M27-S3. Clinical and Laboratory Standards Institute, Wayne, PA

3. ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398–405

4. O. A.Cornely, M. Bassetti, T. Calandra, J. Garbino, B. J. Kullberg,O. Lortholary, W.Meersseman, M.Akova, Arendrup, S. Arikan-Akdagli, J. Bille, Castagnola,M.Cuenca-Estrella, J. P. Donnelly, A. H. Groll, R. Herbrecht, W. W.Hope, H.E. Jensen, C. Lass-Flo¨ rl,G. Petrikkos,M. D. Richardson, E. Roilides, P. E.Verweij, C. Viscoli and A. J. Ullmann for the ESCMID Fungal Infection Study Group (EFISG). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: nonneutropenic adult patients. Clin Microbiol Infect 2012; 18 (7):19–37.

5. Maiken Cavling Arendrup. Candida and Candidaemia. Susceptibility and Epidemiology. Dan Med J 2013; 60(11):B4698.

6. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Fourth Informational Supplement, M27-S4. 2012

7. Pfaller M.A., Shawn A. Messer, Leah N. Woosley, Ronald N. Jones, Mariana Castanheira. Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance. J. Clin. Microbiol. August 2013 . – Vol. 51 № 8: 2571–2581

8. Pfaller MA, Andes D, Arendrup MC, Diekema DJ, Espinel- Ingroff A, Alexander BD, Brown SD, Chaturvedi V, Fowler CL, Ghannoum MA, Johnson EM, Knapp CC, Motyl MR, Ostrosky- Zeichner L, Walsh TJ.. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn. Microbiol. Infect. Dis. 2011; 70: 330–343

9. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D, CLSI Subcommittee for Antifungal Susceptibility Testing. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 2010; 13:180–195

10. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn. Microbiol. Infect. Dis. 2011; 69:45–50

11. Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J. Clin. Microbiol. 2012; 50:2846–2856

12. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J. Clin. Microbiol. 2012; 50:1199–1203

13. Pfaller MA, Woosley LN, Messer SA, Jones RN, Castanheira M. Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme. Mycopathologia 2012; 174:259–271

14. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011, doi:10.1016/j.drup.2011.01.004

15. Bagirova N.S., Dmitrieva N.V, Hachaturova V.A. In vitro aktivnost‘ flukonazola i vorikonazola protiv drozhzhevyh gribov, vydelennyh u onkologicheskih bol‘nyh. Soprovoditel‘naja terapija v onkologii, 2007; № 1-2. C. 73-81

16. Arendrup M. C., G.Garcia-Effron, C. Lass-FloЁrl, A. Gomez Lopez, J. Luis Rodriguez-Tudela, M. Cuenca-Estrella, and D.S. Perlin. Echinocandin Susceptibility Testing of Candida Species: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest Media. Antimicrob. Aagents and Chemother., Jan. 2010; 54 (1): 426–439

17. Cuesta Isabel, Concha Bielza, Manuel Cuenca-Estrella, Pedro Larran aga, and Juan L. Rodr guez-Tudela. Evaluation by Data Mining Techniques of Fluconazole Breakpoints Established by the Clinical and Laboratory Standards Institute (CLSI) and Comparison with Those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Antimicrob. Aagents and Chemother., Apr. 2010; 54(4): 1541–1546

18. Alexander B.D., Johnson M.D., Pfeiffer C.D., Jimenes-Ortigosa C., Canania J., Booker R., et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutation and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 2013; 56:1724-32

19. Cuenca-Estrella M., Verweij P.E., Arendrup M.C., Arikan-Akdagli S., Bille J., Donnelly J.P. et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnosis procedures. Clin. Microbiol. Infect. 2012; 18(7): 9-18

20. Shields R.K., Nguyen M.N., Press E.G., Updike C.L., Clancy C.J. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob. Agents Chemother. 2013; 57: 3528-35

21. Ben-Ami R., Y. Hilerowicz, A. Novikov, M. Giladi. The impact of new epidemiological cutoff values on Candida glabrata resistance rates and concordance between testing methods. Diagnostic Microbiol. And Infect Dis. 2014; 79: 209-213

22. Cuenca-Estrella M., A. Gomez-Lopez, A. Alastruey-Izquierdo, L. Bernal-Martinez, I. Cuesta, M.J. Buitrago, and J.L. Rodriguez-Tudela. Comparison of the VITEK 2 Antifungal Susceptibility System with the CLSI and the EUCAST Broth Microdilution Reference methods and with the Sensititre Yeast-One and the Etest Techniques for the Detection in Vitro of Antifungal Resistance in Yeasts. J. Clin. Microbiol., May 2010 ; 48 (5): 1782–1786

23. Pfaller M.A, L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar, and D. J. Diekema. Wild-Type MIC Distributions and Epidemiological Cutoff Values for Posaconazole and Voriconazole and Candida spp. as Determined by 24-Hour CLSI Broth Microdilution. J. Clin. Microbiol. 2011; 49(2): 630–637


Дополнительные файлы

Для цитирования: Багирова Н.С., Дмитриева Н.В. Определение резистентности Candida spp. к антифунгальным препаратам системного действия эпсилометрическим методом (Е-тест) с учетом видо-специфических особенностей кандид. Журнал инфектологии. 2015;7(3):91-102. https://doi.org/10.22625/2072-6732-2015-7-3-91-102

For citation: Bagirova N.S., Dmitrieva N.V. Determination of resistance Candida spp. to antifungal agents with systemic action epsilometric method (E-test) with the species-specific characteristics of Candida. Journal Infectology. 2015;7(3):91-102. (In Russ.) https://doi.org/10.22625/2072-6732-2015-7-3-91-102

Просмотров: 206

Обратные ссылки

  • Обратные ссылки не определены.


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2072-6732 (Print)
ISSN 2499-9865 (Online)